春季角結膜炎治療薬の世界市場:インサイト・疫学・市場予測

◆英語タイトル:Vernal keratoconjunctivitis- Market Insight, Epidemiology and Market Forecast -2030
◆商品コード:DELV20JU138
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年6月
◆ページ数:200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(138名様閲覧)USD6,950 ⇒換算¥729,750見積依頼/購入/質問フォーム
Three UserUSD10,425 ⇒換算¥1,094,625見積依頼/購入/質問フォーム
Site LicenseUSD13,900 ⇒換算¥1,459,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s “Vernal keratoconjunctivitis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Vernal keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Vernal keratoconjunctivitis market report provides current treatment practices, emerging drugs, Vernal keratoconjunctivitis market share of the individual therapies, current and forecasted Vernal keratoconjunctivitis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Vernal keratoconjunctivitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
MEA (Saudi Arabia, Egypt)
China
Russia

Study Period: 2017-2030

Vernal keratoconjunctivitis Disease Understanding and Treatment Algorithm
Vernal keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterized by limbal gelatinous hypertrophy and/or upper tarsal giant conjunctival papillae. It is an IgE-mediated and T cell-mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte, and structural cell activation are involved. The disease may present in three clinical forms: tarsal, limbal and mixed form.

VKC mostly affects children and young adults living in warm climates worldwide. It begins typically in the first decade of life and resolves spontaneously after puberty even though in the most severe cases it can leave permanent lesions. It is characterized by intense itching, tearing, mucous secretions, and severe photophobia.

Diagnosis

There are no established diagnostic criteria for VKC and the diagnosis is based on the characteristic signs and symptoms of the disease. Because of no precise diagnostic criteria have been established, many mild or atypical cases may escape the diagnosis. Hyperemia, itching, photophobia, tearing and mucus discharge are typical symptoms of VKC. Large papilla on the upper tarsal conjunctiva and corneoscleral junction are hallmarks of VKC.

Continued in the report…

Treatment

Currently, there is no defined standard treatment algorithm for VKC, but there are many options available, and treatment should be tailored to the individual. Individuals treated should be monitored closely for the development of any corneal complications.

The current treatment options include mast cell stabilizers, antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs), topical corticosteroids, cyclosporine, and tacrolimus.

Mast cell stabilizers prevent the degranulation of mast cells. Commonly used mast cell stabilizers include cromolyn sodium and lodoxamide, which are frequently used as first-line therapy. Antihistamines are sometimes used in the treatment of VKC. They are most often used in alleviating the symptoms of mild disease, but they have limited utility in severe cases. More recent medications that combine antihistamine properties with mast cell stabilization include ketotifen and olopatadine.

NSAIDs (preservative‐free diclofenac (0.1%) eye drops) may be used in conjunction with other topical anti-inflammatory medications to provide rapid relief of symptoms; however, they have limited utility in those patients with corneal involvement.

Topical corticosteroids are one of the most effective drugs to control the signs and symptoms of VKC. Because of complications associated with their prolonged use, these are not prescribed as first‐line treatment. Cyclosporine, a fungal metabolite, decreases the signs and symptoms of VKC. Low doses of cyclosporine are used in some cases of VKC.

Tacrolimus has shown efficacy in clinical trials and it can be also used in patients with corneal involvement. Mitomycin‐C (0.01%) eyedrops were shown to decrease the mucous discharge, conjunctival hyperemia and limbal edema in VKC patients refractory to topical steroids and mast‐cell stabilizers. The allergen-specific immunotherapy (SIT) is indicated only when a clearly defined systemic hypersensitivity to identified allergens exists.

Vernal keratoconjunctivitis Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of VKC, Diagnosed Prevalent Population of VKC, Gender-specific Diagnosed Prevalent Population of VKC, Type-specific Diagnosed Prevalent Population of VKC, Severity-specific Diagnosed Prevalent Population of VKC, and Age-specific Diagnosed Prevalent Population of VKC scenario of VKC in the global market from 2017 to 2030.

Key Findings

The increasing population and rising prevalence of VKC generates a large patient population in the global market. In 2017, a total of 4,752,356 patients were affected by VKC in the global market.
China contributes the largest share among EU-5, and Japan, with 2,248,706 cases in 2017.
The total diagnosed prevalent population of VKC was 2,943,057 in the global market.

Country Wise- Vernal keratoconjunctivitis Epidemiology

The epidemiology segment also provides the Vernal keratoconjunctivitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Vernal keratoconjunctivitis Drug Chapters
Drug chapter segment of the Vernal keratoconjunctivitis report encloses the detailed analysis of Vernal keratoconjunctivitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Vernal keratoconjunctivitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

Verkazia/Verkacia: Santen

Verkazia/Verkacia (0.1% cyclosporine), an immunomodulator that targets the underlying cause of the inflammation at the surface of the eye, controls the allergic response and inflammation. It is approved for the treatment of severe VKC in children from 4 years of age and adolescents.

Verkazia works differently to other licensed treatments, as it directly targets the underlying cause of the inflammation at the surface of the eye, controlling the allergic response and inflammation. It can be used over a sustained period which means that the use of steroids can be reduced. In clinical trials, Verkazia has been shown to significantly improve damage to the surface of the eye and reduce symptoms of severe VKC in children and adolescents (54% improvement vs. the control group given cationic emulsion. Verkazia was shown to improve the main symptoms of VKC: 68% improvement in light sensitivity; 58% in tearing; 72% in itching; and 67% in discharge.

Products detail in the report…

Lodoxamide/Alomide: Novartis Pharmaceuticals/Alcon

Lodoxamide 0.1% (Alomide) is a mast cell stabilizer that is approximately 2,500 times more potent than cromolyn in the prevention of histamine release in several animal models. Lodoxamide is effective in reducing tryptase and histamine levels and the recruitment of inflammatory cells in the tear fluid after allergen challenge, as well as tear eosinophil cationic protein and leukotrienes (BLT and CysLT1) when compared to cromolyn. In early clinical trials lodoxamide (0.1%) was shown to deliver greater and earlier relief in patients with more chronic forms, such as VKC, including upper tarsal papilla, limbal signs (papilla, hyperemia, and Trantas’ dots) and conjunctival discharge, and to improve epithelial defects seen in the chronic forms of conjunctivitis (VKC, GPC) than cromolyn. In patients with allergic conjunctivitis, it is approved for the treatment of VKC at a concentration of 0.1% four times daily. Lodoxamide may be used continuously for 3 months in children older than 2 years of age.

Products detail in the report…

Talymus/Tacrolimus: Senju Pharmaceutical

Tacrolimus is a strong, nonsteroidal immune suppressant isolated from Streptomyces tsukubaensi. It binds to FK506-binding proteins in T-lymphocytes and inhibits calcineurin activity. Calcineurin inhibition suppresses dephosphorylation of the nuclear factor of activated T-cells and its transfer into the nucleus, which suppresses the formation of T-helper (Th) 1 (interleukin [IL]-2, interferon γ) and Th2 cytokines (IL-4, IL-5). Tacrolimus also inhibits histamine release from mast cells, which is thought to alleviate allergic symptoms. Tacrolimus is up to 100 times more potent than cyclosporine.

Tacrolimus ointment is used widely for the treatment of atopic dermatitis. Topical tacrolimus (0.02–0.1%) has also been used to treat giant papillary conjunctivitis, AKC, and VKC, with good results. Furthermore, a tacrolimus 0.1% ophthalmic suspension has been used for the treatment of AKC and VKC with only 4 weeks of follow-up. Tacrolimus, 0.1% ointment, is a safe and effective treatment for VKC refractory to standard treatment and is used as a substitute for steroid treatments used to controlled disease activity.

Products detail in the report…

List to be continued in the report…

Vernal keratoconjunctivitis Emerging Drugs

Antolimab (AK002): Allakos

Antolimab (AK002), is an investigational therapeutic antibody that targets siglec-8, an inhibitory receptor found on the surface of mast cells and eosinophils. By targeting siglec-8, antolimab offers the potential to treat a broad range of serious, complex inflammatory diseases.

Allakos has conducted an open-label Phase Ib clinical trial in patients with three forms of severe allergic conjunctivitis (atopic keratoconjunctivitis, VKC, and perennial allergic conjunctivitis refractory to topical treatments). After treatment with antolimab in the Phase Ib study, there was a reduction of patient-reported ocular symptoms and the physician assessed signs and symptoms. Patients also reported improvements in the severity of comorbid atopic dermatitis, asthma, and rhinitis symptoms.

Products detail in the report…

Bertilimumab/iCo-008: iCo Therapeutics

Bertilimumab (also known as iCo-008 or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins that act as messenger molecules between the cells of the immune system. Bertilimumab has shown a good safety profile and has shown evidence of efficacy in a severe allergy indication.

More recently, bertilimumab has been investigated in two Phase II trials. The first trial targeted patients with a skin condition called bullous pemphigoid and revealed good safety and efficacy results. A Phase II clinical trial for patients with VKC and/or atopic keratoconjunctivitis (involving cornea and conjunctiva) is in preparation.

Products detail in the report…

Nomacopan: Akari Therapeutics

Nomacopan, which is a second-generation complement inhibitor, acts on complement component-C5, preventing the release of C5a and formation of C5b-9 (also known as the membrane attack complex, or MAC), and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response. It is a small recombinant protein (16,740 Da) derived from a protein originally discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Additionally, Nomacopan’s biophysical properties allow it to be potentially used in a variety of formulations, including subcutaneous, intravenous, topical or inhaled routes of administration. Currently, Akari Therapeutics is investigating the molecule in phase I/II clinical trial in patients with atopic keratoconjunctivitis (including VKC, Sjögren’s syndrome, and mucous membrane pemphigoid).

Products detail in the report…

List to be continued in the report…

Vernal keratoconjunctivitis Market Outlook
Treatment of VKC requires multiple approaches that include conservative measures and pharmacologic treatment. Patients and parents should be made aware of the prolonged duration of disease, its chronic evolution, and possible complications. Treatment should be based on the duration and frequency of symptoms and the severity of corneal involvement.

Currently available topical drugs for allergic conjunctivitis belong to several pharmacologic classes, such as vasoconstrictors, antihistamines, mast cell stabilizers, ‘dual-acting’ agents (with antihistaminic and mast cell stabilizing properties), non-steroidal anti-inflammatory agents, corticosteroids, and immunosuppressive drugs.

Mast cell stabilizers are the first-line drugs for VKC. Several studies have demonstrated the efficacy of 2% and 4% sodium cromoglicate (DSCG, cromolyn), nedocromil sodium 2%, lodoxamide tromethamine 0.1%, and spaglumic acid 4%.

Ocular drugs with antihistaminic activity may offer therapeutic advantages to patients with allergic conjunctivitis, including VKC, by inhibiting proinflammatory cytokine secretion from conjunctival epithelial cells. The first-generation antihistamines pheniramine and antazoline have a long safety record. The newer antihistamines such as levocabastine hydrochloride 0.5% and emedastine difumarate 0.05% have a longer duration of action (4–6 h) and are better tolerated than their predecessors.

A meta-analysis of randomized clinical trials in VKC showed a large number of studies evaluated the efficacy of common anti-allergic eye drops (levocabastine, lodoxamide, mipragoside, N-acetyl aspartyl glutamic acid, nedocromil sodium, DCG). Among these, lodoxamide appeared to be the most effective.

Papilock mini and Verkazia both produced by Santen (Osaka, Japan) are specifically indicated for the treatment of VKC.

Generally, NSAIDs employed in ocular allergy treatment inhibit both cyclooxygenase (COX)-1 and COX-2 enzymes. Also, Ketorolac, diclofenac and pranoprofen may be valid alternatives to steroids, since they have a proven effect on itching, intercellular adhesion molecule-1 expression, and tear tryptase levels. Indomethacin 1%, ketorolac 0.5%, and diclofenac 0.1% have shown effectiveness in the treatment of VKC.

Aspirin 0.5–1 g/day has been shown as a steroid-sparing factor in the treatment of VKC; however, it should be used with caution because of the well-known possible side effects.

In severe cases, systemic treatment with T-lymphocyte signals transduction inhibitors such as Cyclosporine A or tacrolimus may ameliorate both the dermatologic and ocular manifestations in critical patients who are refractory to conventional treatment.

Omalizumab, an anti-IgE recombinant, humanized, non-anaphylactogenic antibody, directed against the receptor-binding domain of IgE, may be used in VKC patients with high levels of total serum IgE. Calcineurin inhibitors are off-label treatments in the European Union.

As discussed, the current treatment for VKC depends solely on the use of antihistamines, mast cell inhibitors, and several other classes. But till now the treatment is only supportive and is not that effective. But due to the advancement of technology and a better understanding of the disease, several companies are trying to modify the treatment of VKC.

According to DelveInsight, VKC global market is expected to change in the study period 2017–2030.

Key Findings

The market size of VKC in the global market was USD 307.89 million in 2017.
According to the estimates, the highest market size of VKC is found in China followed by Japan, and Russia.
Among the MENA regions, the highest market share is contributed by Egypt, followed by Saudi Arabia.
The upcoming therapy AK002 is anticipated to reach the market by 2023 (in Europe).

The United States Market Outlook

This section provides the total Vernal keratoconjunctivitis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Vernal keratoconjunctivitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Vernal keratoconjunctivitis market size and market size by therapies in Japan is also mentioned.

MEA Region Market Outlook

The total VKC market size and market size by therapies in Saudi Arabia, Egypt and the United Arab Emirates are provided in this section

China Market Outlook

The total VKC market size and market size by therapies in China are provided

Russia Market Outlook

This section provides the total VKC market size and; market size by therapies in Russia

Vernal keratoconjunctivitis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Vernal keratoconjunctivitis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Vernal keratoconjunctivitis market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Vernal keratoconjunctivitis Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Vernal keratoconjunctivitis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Vernal keratoconjunctivitis emerging therapies.

Reimbursement Scenario in Vernal keratoconjunctivitis
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Vernal keratoconjunctivitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Vernal keratoconjunctivitis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Vernal keratoconjunctivitis Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of Vernal keratoconjunctivitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Vernal keratoconjunctivitis epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Vernal keratoconjunctivitis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Vernal keratoconjunctivitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Vernal keratoconjunctivitis market

Report Highlights
The increasing prevalence of the disease along with promising emerging pipeline therapies will positively drive the VKC market.
The companies and academics are working to assess challenges and seek opportunities that could influence VKC R&D.
Major players are involved in developing therapies for VKC. Launch of emerging therapies will significantly impact the VKC market.
Our in-depth analysis of the pipeline assets across different stages of development (phase II and phase I), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Vernal keratoconjunctivitis Report Insights
Patient Population
Therapeutic Approaches
Vernal keratoconjunctivitis Pipeline Analysis
Vernal keratoconjunctivitis Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Vernal keratoconjunctivitis Report Key Strengths
11 Years Forecast
7MM Coverage
Vernal keratoconjunctivitis Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Vernal keratoconjunctivitis Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions
Market Insights:

What was the Vernal keratoconjunctivitis market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Vernal keratoconjunctivitis total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Vernal keratoconjunctivitis market size during the forecast period (2017-2030)?
At what CAGR, the Vernal keratoconjunctivitis market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Vernal keratoconjunctivitis market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Vernal keratoconjunctivitis market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Vernal keratoconjunctivitis?
What is the historical Vernal keratoconjunctivitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Vernal keratoconjunctivitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Vernal keratoconjunctivitis?
Out of all 7MM countries, which country would have the highest prevalent population of Vernal keratoconjunctivitis during the forecast period (2017-2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the Vernal keratoconjunctivitis treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Vernal keratoconjunctivitis in the USA, Europe, and Japan?
What are the Vernal keratoconjunctivitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Vernal keratoconjunctivitis?
How many therapies are developed by each company for Vernal keratoconjunctivitis treatment?
How many are emerging therapies in mid-stage, and late stage of development for Vernal keratoconjunctivitis treatment?
What are the key collaborations (Industry – Industry, Industry – Academia), Mergers and acquisitions, licensing activities related to the Vernal keratoconjunctivitis therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Vernal keratoconjunctivitis and their status?
What are the key designations that have been granted for the emerging therapies for Vernal keratoconjunctivitis?
What are the global historical and forecasted market of Vernal keratoconjunctivitis?
Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Vernal keratoconjunctivitis market
To understand the future market competition in the Vernal keratoconjunctivitis market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Vernal keratoconjunctivitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Vernal keratoconjunctivitis market
To understand the future market competition in the Vernal keratoconjunctivitis market

【レポートの目次】

1. Key Insights

2. Executive Summary of Vernal keratoconjunctivitis (VKC)

3. Vernal keratoconjunctivitis (VKC): Market Overview at a Glance

3.1. Total Market Share (%) Distribution of VKC in 2017

3.2. Total Market Share (%) Distribution of VKC in 2030

4. Disease Background and Overview: Vernal keratoconjunctivitis (VKC)

4.1. Introduction

4.2. Signs and Symptoms of VKC

4.2.1. Signs

4.3. Causes

4.4. Risk Factors

4.5. Grades of VKC

4.6. Pathophysiology

4.6.1. Mediators in VKC

4.6.2. Cells in VKC

4.7. Histopathology

4.8. Diagnosis of VKC

5. Case Reports

5.1. Vernal Keratoconjunctivitis: A Teaching Case Report

5.2. Ocular surface disease: A case of vernal keratoconjunctivitis

5.3. Topical and Oral Cyclosporine for a Case of Severe Limbal Vernal Keratoconjunctivitis with Complete Corneal Involvement

5.4. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab

5.5. Recalcitrant Atopic Keratoconjunctivitis in Children: A Case Report and Literature Review

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

7. United States Epidemiology

7.1. Assumptions and Rationale

7.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the United States

7.3. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

7.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

7.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in the United States

7.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

7.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United States

8. EU5 Epidemiology

8.1. Assumptions and Rationale

8.2. Germany Epidemiology

8.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) Based on Symptoms in Germany

8.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany

8.3. France Epidemiology

8.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France

8.3.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in France

8.3.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in France

8.4. Italy Epidemiology

8.4.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.4.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Italy

8.5. Spain Epidemiology

8.5.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.2. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.3. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.5.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Spain

8.6. United Kingdom Epidemiology

8.6.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the UK

8.6.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK

8.6.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK

8.6.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

8.6.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

8.6.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

9. Japan Epidemiology

9.1.1. Assumptions and Rationale

9.1.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

9.1.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Japan

10. MEA Region Epidemiology

10.1. Assumptions and Rationale

10.2.Saudi Arabia Epidemiology

10.2.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.2.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Saudi Arabia

10.3.Egypt Epidemiology

10.3.1. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.2. Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.3. Gender-specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.4. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.5. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

10.3.6. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt

11. China Epidemiology

11.1. Assumptions and Rationale

11.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China

11.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in China

11.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

11.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

11.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

11.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in China

12. Russia Epidemiology

12.1. Assumptions and Rationale

12.2. Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia

12.3. Diagnosed Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Russia

12.4. Gender-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

12.5. Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

12.6. Severity-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

12.7. Age-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Russia

13. Current Treatment and Medical Practices

13.1. Treatment of VKC

13.2. Practical management of VKC

13.3. Treatment Guidelines

13.3.1. Japanese guidelines for allergic conjunctival diseases 2017

14. Unmet Needs

15. Marketed Drugs

15.1. Verkazia/Verkacia: Santen

15.1.1. Product Description

15.1.2. Regulatory Milestones

15.1.3. Clinical Development

15.1.4. Safety and Efficacy

15.1.5. Product Profile

15.2. Lodoxamide/Alomide: Novartis Pharmaceuticals/Alcon

15.2.1. Product Description

15.2.2. Regulatory Milestones

15.2.3. Product Profile

15.3. Talymus/Tacrolimus: Senju Pharmaceutical

15.3.1. Product Description

15.3.2. Regulatory Milestones

15.3.3. Clinical Development

15.3.4. Safety and Efficacy

15.3.5. Product Profile

15.4. Papilock Mini: Santen

15.4.1. Product Description

15.4.2. Regulatory Milestones

15.4.3. Product Profile

16. Emerging Drugs

16.1. Antolimab (AK002): Allakos

16.1.1. Product Description

16.1.2. Regulatory Milestones

16.1.3. Clinical Development

16.1.4. Safety and Efficacy

16.1.5. Product Profile

16.2. Bertilimumab/iCo-008: iCo Therapeutics

16.2.1. Product Description

16.2.2. Regulatory Milestones

16.2.3. Safety and Efficacy

16.2.4. Product Profile

16.3. Nomacopan: Akari Therapeutics

16.3.1. Product Description

16.3.2. Regulatory Milestones

16.3.3. Clinical Development

16.3.4. Safety and Efficacy

16.3.5. Product Profile

17. Vernal Keratoconjunctivitis (VKC): 7MM Market Analysis

17.1. Key Findings

17.2. Market Methodology

17.3. Market Size of Vernal Keratoconjunctivitis (VKC) in the 6MM

17.4. Market Size of Vernal Keratoconjunctivitis (VKC) by Therapies in the 6MM

18. United States

18.1. 7MM: Market Outlook

18.2. United States Market Size

18.2.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in the US

18.2.2. Market Size of Vernal Keratoconjunctivitis (VKC) by Therapies in the US

19. EU-5 countries

19.1.Germany Market Size

19.1.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Germany

19.1.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Germany

19.2.France Market Size

19.2.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in France

19.2.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in France

19.3.Italy Market Size

19.3.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Italy

19.3.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Italy

19.4.Spain Market Size

19.4.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Spain

19.4.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Spain

19.5.United Kingdom Market Size

19.5.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in the United Kingdom

19.5.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the UK

20. Japan

20.1. Japan Market Size

20.1.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Japan

20.1.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Japan

21. MEA countries Market Outlook

21.1.Saudi Arabia Market Size

21.1.1. Total Market size of VKC in Saudi Arabia

21.1.2. Market Size of VKC by therapies in Saudi Arabia

21.2.Egypt Market Size

21.2.1. Total Market size of VKC in Egypt

21.2.2. Market Size of VKC by therapies in Egypt

22. China: Market Outlook

22.1. China Market Size

22.1.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in China

22.1.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in China

23. Russia Market Outlook

23.1. Russia Market Size

23.1.1. Total Market size of Vernal Keratoconjunctivitis (VKC) in Russia

23.1.2. Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Russia

24. Market Drivers

25. Market Barriers

26. Reimbursement and Market Access

27. SWOT Analysis

28. KOL Views

29. Appendix

29.1. Bibliography

29.2. Report Methodology

30. DelveInsight Capabilities

31. Disclaimer

32. About DelveInsight

Table 1 :Summary of Vernal Keratoconjunctivitis (VKC), Market, Epidemiology and Key Events (2017–2030)

Table 2 :Clinical grading (from 0 to 5) of vernal keratoconjunctivitis

Table 3 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the Total Major Markets (2017–2030)

Table 4 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Table 5 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Table 6 :Gender-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Table 7 :Type-specific Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Table 8 :Severity-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Table 9 :Age-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Table 10 :Total Prevalent Population of VKC in Germany (2017–2030)

Table 11 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany (2017–2030)

Table 12 :Gender-Specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Table 13 :Type-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Table 14 :Severity-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Table 15 :Age-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Table 16 :Total Prevalent Population of VKC in France (2017–2030)

Table 17 :Diagnosed Prevalent Population of VKC in France (2017–2030)

Table 18 :Gender-specific Diagnosed Prevalence of VKC in France (2017–2030)

Table 19 :Type-specific Diagnosed Prevalence of VKC in France (2017–2030)

Table 20 :Severity-specific Diagnosed Prevalence of VKC in France (2017–2030)

Table 21 :Age-specific Diagnosed Prevalence of VKC in France (2017–2030)

Table 22 :Total Prevalent Population of VKC in Italy (2017–2030)

Table 23 :Diagnosed Prevalent Population of VKC in Italy (2017–2030)

Table 24 :Gender-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Table 25 :Type-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Table 26 :Severity-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Table 27 :Age-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Table 28 :Total Prevalent Population of VKC in Spain (2017–2030)

Table 29 :Diagnosed Prevalent Population of VKC in Spain (2017–2030)

Table 30 :Gender-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Table 31 :Type-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Table 32 :Severity-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Table 33 :Age-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Table 34 :Total Prevalent Population of VKC in the UK (2017–2030)

Table 35 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Table 36 :Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Table 37 :Type-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)

Table 38 :Severity-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)

Table 39 :Age-specific Diagnosed Prevalence of VKC in the UK (2017–2030)

Table 40 :Total Prevalent Population of VKC in Japan (2017–2030)

Table 41 :Diagnosed Prevalent Population of VKC in Japan (2017–2030)

Table 42 :Gender-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Table 43 :Type-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Table 44 :Severity-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Table 45 :Age-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Table 46 :Total Prevalent Population of VKC in Saudi Arabia (2017–2030)

Table 47 :Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Table 48 :Gender-Specific Prevalence of VKC in Saudi Arabia (2017–2030)

Table 49 :Type-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Table 50 :Severity-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Table 51 :Age-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Table 52 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Table 53 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Table 54 :Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Table 55 :Type-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Table 56 :Severity-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Table 57 :Age-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Table 58 :Total Prevalent Population of VKC in China (2017–2030)

Table 59 :Diagnosed Prevalent Population of VKC in China (2017–2030)

Table 60 :Gender-specific Diagnosed Prevalence of VKC in China (2017–2030)

Table 61 :Type-specific Diagnosed Prevalence of VKC in China (2017–2030)

Table 62 :Severity-specific Diagnosed Prevalence of VKC in China (2017–2030)

Table 63 :Age-specific Diagnosed Prevalence of VKC in China (2017–2030)

Table 64 :Total Prevalent Population of VKC in Russia (2017–2030)

Table 65 :Diagnosed Prevalent Population of VKC in Russia (2017–2030)

Table 66 :Gender-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Table 67 :Type-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Table 68 :Severity-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Table 69 :Age-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Table 70 :Topical ocular allergy medications for the treatment of vernal keratoconjunctivitis

Table 71 :Clinical grading of vernal keratoconjunctivitis and therapeutical approach

Table 72 :Verkazia, Clinical Trial Description, 2020

Table 73 :Tacrolimus, Clinical Trial Description, 2020

Table 74 :Antolimab (AK002), Clinical Trial Description, 2020

Table 75 :Nomacopan, Clinical Trial Description, 2020

Table 76 :Market Size of Vernal Keratoconjunctivitis (VKC) in the Total Markets in USD Million (2017–2030)

Table 77 :Market Size of Vernal Keratoconjunctivitis by therapies in the Total Markets, in USD Million (2017–2030)

Table 78 :The US Market Size of VKC in USD Million (2017–2030)

Table 79 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the US, in USD Million (2017–2030)

Table 80 :Germany Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)

Table 81 :Market Size of VKC by therapies in Germany, in USD Million (2017–2030)

Table 82 :France Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)

Table 83 :Market Size of VKC by therapies in France, in USD Million (2017–2030)

Table 84 :Italy Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)

Table 85 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Italy, in USD Million (2017–2030)

Table 86 :Spain Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)

Table 87 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Spain, in USD Million (2017–2030)

Table 88 :The UK Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)

Table 89 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the UK, in USD Million (2017–2030)

Table 90 :Japan Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)

Table 91 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Japan, in USD Million (2017–2030)

Table 92 :Topical medication for the treatment of Vernal Keratoconjunctivitis

Table 93 :Saudi Arabia Market Size of VKC in USD Million (2017–2030)

Table 94 :Market Size of VKC by therapies in Saudi Arabia, in USD Million (2017–2030)

Table 95 :Egypt Market Size of VKC in USD Million (2017–2030)

Table 96 :Market Size of VKC by therapies in Egypt, in USD Million (2017–2030)

Table 97 :China Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)

Table 98 :Market Size of VKC by therapies in China, in USD Million (2017–2030)

Table 99 :Russia Market Size of Vernal Keratoconjunctivitis (VKC) in USD Million (2017–2030)

Table 100 :Market Size of VKC by therapies in Russia, in USD Million (2017–2030)

List of Figures:

Figure 1 :Anatomy and symptoms of vernal keratoconjunctivitis

Figure 2 :Common symptoms of VKC

Figure 3 :Clinical sign of vernal keratoconjunctivitis

Figure 4 :Risk factors of VKC

Figure 5 :Different therapeutic approach proposed for the different vernal keratoconjunctivitis grades

Figure 6 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the Total Major Markets (2017–2030)

Figure 7 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Figure 8 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the US (2017–2030)

Figure 9 :Gender-Specific Diagnosed Prevalence of VKC in the US (2017–2030)

Figure 10 :Type-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Figure 11 :Severity-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Figure 12 :Age-specific Diagnosed Prevalence of VKC in the US (2017–2030)

Figure 13 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Germany (2017–2030)

Figure 14 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Germany (2017–2030)

Figure 15 :Gender-Specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Figure 16 :Type-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Figure 17 :Severity-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Figure 18 :Age-specific Diagnosed Prevalence of VKC in Germany (2017–2030)

Figure 19 :Total Prevalent Population of VKC in France (2017–2030)

Figure 20 :Diagnosed Prevalent Population of VKC in France (2017–2030)

Figure 21 :Gender-specific Diagnosed Prevalence of VKC in France (2017–2030)

Figure 22 :Type-specific Diagnosed Prevalence of VKC in France (2017–2030)

Figure 23 :Severity-specific Diagnosed Prevalence of VKC in France (2017–2030)

Figure 24 :Age-specific Diagnosed Prevalence of VKC in France (2017–2030)

Figure 25 :Total Prevalent Population of VKC in Italy (2017–2030)

Figure 26 :Diagnosed Prevalent Population of VKC in Italy (2017–2030)

Figure 27 :Gender-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Figure 28 :Type-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Figure 29 :Severity-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Figure 30 :Age-specific Diagnosed Prevalence of VKC in Italy (2017–2030)

Figure 31 :Total Prevalent Population of VKC in Spain (2017–2030)

Figure 32 :Diagnosed Prevalent Population of VKC in Spain (2017–2030)

Figure 33 :Gender-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Figure 34 :Type-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Figure 35 :Severity-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Figure 36 :Age-specific Diagnosed Prevalence of VKC in Spain (2017–2030)

Figure 37 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Figure 38 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Figure 39 :Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in the UK (2017–2030)

Figure 40 :Type-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)

Figure 41 :Severity-specific Diagnosed Prevalence of VKC in the United Kingdom (2017–2030)

Figure 42 :Age-specific Diagnosed Prevalence of VKC in the UK (2017–2030)

Figure 43 :Total Prevalent Population of VKC in Japan (2017–2030)

Figure 44 :Diagnosed Prevalent Population of VKC in Japan (2017–2030)

Figure 45 :Gender-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Figure 46 :Type-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Figure 47 :Severity-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Figure 48 :Age-specific Diagnosed Prevalence of VKC in Japan (2017–2030)

Figure 49 :Total Prevalent Population of VKC in Saudi Arabia (2017–2030)

Figure 50 :Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 51 :Gender-Specific Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 52 :Type-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 53 :Severity-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 54 :Age-specific Diagnosed Prevalence of VKC in Saudi Arabia (2017–2030)

Figure 55 :Total Prevalent Population of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Figure 56 :Diagnosed Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Figure 57 :Gender-Specific Prevalence of Vernal Keratoconjunctivitis (VKC) in Egypt (2017–2030)

Figure 58 :Type-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Figure 59 :Severity-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Figure 60 :Age-specific Diagnosed Prevalence of VKC in Egypt (2017–2030)

Figure 61 :Total Prevalent Population of VKC in China (2017–2030)

Figure 62 :Diagnosed Prevalent Population of VKC in China (2017–2030)

Figure 63 :Gender-specific Diagnosed Prevalence of VKC in China (2017–2030)

Figure 64 :Type-specific Diagnosed Prevalence of VKC in China (2017–2030)

Figure 65 :Severity-specific Diagnosed Prevalence of VKC in China (2017–2030)

Figure 66 :Age-specific Diagnosed Prevalence of VKC in China (2017–2030)

Figure 67 :Total Prevalent Population of VKC in Russia (2017–2030)

Figure 68 :Diagnosed Prevalent Population of VKC in Russia (2017–2030)

Figure 69 :Gender-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Figure 70 :Type-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Figure 71 :Severity-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Figure 72 :Age-specific Diagnosed Prevalence of VKC in Russia (2017–2030)

Figure 73 :Allergist and Eye Care Specialists: Multidisciplinary Approach

Figure 74 :Treatment algorithm for vernal keratoconjunctivitis

Figure 75 :Treatment of ACDs: proliferative (vernal keratoconjunctivitis)

Figure 76 :Unmet Needs

Figure 77 :Market Size of Vernal Keratoconjunctivitis (VKC) in the Total Markets in USD Million (2017–2030)

Figure 78 :Market Size of VKC by therapies in the Total Markets, in USD Million (2017–2030)

Figure 79 :Market Size of Vernal Keratoconjunctivitis (VKC) in the US, USD Millions (2017–2030)

Figure 80 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the US, in USD Million (2017–2030)

Figure 81 :Market Size of Vernal Keratoconjunctivitis (VKC) in Germany, USD Millions (2017–2030)

Figure 82 :Market Size of VKC by therapies in Germany, in USD Million (2017–2030)

Figure 83 :Market Size of Vernal Keratoconjunctivitis (VKC) in France, USD Millions (2017–2030)

Figure 84 :Market Size of VKC by therapies in France, in USD Million (2017–2030)

Figure 85 :Market Size of Vernal Keratoconjunctivitis (VKC) in Italy, USD Millions (2017–2030)

Figure 86 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Italy in USD Million (2017–2030)

Figure 87 :Market Size of Vernal Keratoconjunctivitis (VKC) in Spain, USD Millions (2017–2030)

Figure 88 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in Spain in USD Million (2017–2030)

Figure 89 :Market Size of Vernal Keratoconjunctivitis (VKC) in the UK, USD Millions (2017–2030)

Figure 90 :Market Size of Vernal Keratoconjunctivitis (VKC) by therapies in the UK in USD Million (2017–2030)

Figure 91 :Market Size of Vernal Keratoconjunctivitis (VKC) in Japan, USD Millions (2017–2030)

Figure 92 :Market Size of VKC by therapies in Japan in USD Million (2017–2030)

Figure 93 :Market Size of VKC in Saudi Arabia, USD Millions (2017–2030)

Figure 94 :Market Size of VKC by therapies in Saudi Arabia, in USD Million (2017–2030)

Figure 95 :Market Size of VKC in Egypt, USD Millions (2017–2030)

Figure 96 :Market Size of VKC by therapies in Egypt, in USD Million (2017–2030)

Figure 97 :Market Size of Vernal Keratoconjunctivitis (VKC) in China, USD Millions (2017–2030)

Figure 98 :Market Size of VKC by therapies in China in USD Million (2017–2030)

Figure 99 :Market Size of Vernal Keratoconjunctivitis (VKC) in Russia, USD Millions (2017–2030)

Figure 100 :Market Size of VKC by therapies in Russia in USD Million (2017–2030)

Figure 101 :Market Drivers

Figure 102 :Market Barriers

Figure 103 :SWOT analysis of vernal keratoconjunctivitis

Figure 104 :KOL Views

Figure 105 :KOL Views Continued..

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[春季角結膜炎治療薬の世界市場:インサイト・疫学・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆